Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objectives: We investigated vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneously vancomycin-intermediate S. aureus (hetero-VISA) isolates from clinical specimens of hospitalized patients at Hacettepe University over a 4 year period. Methods: Strains were screened for VISA and hetero-VISA by using brain heart infusion agar containing 4 mg/L vancomycin (BHI-V4) and macro Etest. Confirmation of the isolates that were found to have intermediate susceptibility to vancomycin with either of the methods was done by population analysis of subpopulations with reduced susceptibility to vancomycin. The MIC of vancomycin for the isolates grown on BHI-V4 was determined by the microdilution method. Results: Among 256 methicillin-resistant S. aureus (MRSA) isolates, 145 grew on BHI-V4. Forty-six of these were also found to be heterogeneously vancomycin-intermediate strains when screened with the macro Etest. There were no VISA among 256 MRSA tested but 46 (17.97%) S. aureus strains with reduced susceptibility to vancomycin were identified by population analysis. Vancomycin MIC values for all isolates with reduced susceptibility were between ≤0.125 and 4 mg/L. Twelve of the 46 patients with hetero-VISA had a history of previously being treated with vancomycin or teicoplanin. Conclusions: To our knowledge, this study is the first publication showing the presence of hetero-VISA in Turkey. In order to understand the epidemiological relationship between our isolates, molecular typing methods are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984 · cited 2×
“aureus isolate with the following characteristics: (i) reproducible growth on BHI-V4; (ii) a vancomycin MIC of 8–16 mg/L by the broth microdilution method; (iii) a population analysis profile similar to homogeneous VISA control strain Mu50.(1,23) Hetero-VISA was defined as an S.”
Method
Cited by
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Tenover, F. C., & Moellering, R. C. (2007) · Clinical Infectious Diseases · doi:10.1086/513203 · Cited by 452
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
Appelbaum, P. C. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01344.x · Cited by 376
Shariati, A., Dadashi, M., Moghadam, M. T., van Belkum, A., Yaslianifard, S., & Darban-Sarokhalil, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-69058-z · Cited by 329
Bae, I., Federspiel, J. J., Miró, J. M., Woods, C. W., Park, L., Rybak, M. J., Rude, T. H., Bradley, S., Bukovski, S., de la Maria, C. G., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/606027 · Cited by 122
Zhang, S., Sun, X., Chang, W., Dai, Y., & Ma, X. (2015) · PLOS ONE · doi:10.1371/journal.pone.0136082 · Cited by 99
Metadata
- Authors
- Sancak, B., Ercis, S., Menemenlioğlu, D., Çolakoğlu, Ş., & Hasçelik, G.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-26
- Volume
- 56
- Issue
- 3
- Pages
- 519-523
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2115012461
- Cited by
- 83
- References
- 1
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.